Objective—To evaluate effects of zoledronate on
markers of bone metabolism in dogs after transection
of the cranial cruciate ligament (CrCL).
Animals—21 adult dogs.
Procedure—Unilateral CrCL transection was performed
arthroscopically. Dogs were allocated to 3
groups (control group, low-dose zoledronate
[10 µg/kg, SC, q 90 d for 12 months], and high-dose
zoledronate [25 µg/kg, SC, q 90 d for 12 months]).
Serum osteocalcin (OC), serum bone-specific alkaline
phosphatase (BAP), and urine pyridinoline and
deoxypyridinoline concentrations were measured at
0, 1, 3, 6, 9, and 12 months after surgery. Bone mineral
density (BMD) was determined in the distal portion
of the femur and proximal portion of the tibia via
computed tomography at each time point. Data were
analyzed by a repeated-measures ANOVA.
Results—Zoledronate inhibited OC in the high-dose
group at 9 and 12 months and at 12 months in the low-dose
group, compared with the control group. High-dose
zoledronate decreased BAP concentrations 3 and 9
months after surgery. In the control group, BMD was
decreased in the femoral condyle and caudal tibial
plateau. Zoledronate prevented significant BMD decreases
starting 1 month after transection, compared with
control dogs. In the caudomedial aspect of the tibial
plateau, both zoledronate groups had significant increases
in BMD after 3 months, compared with control dogs.
Conclusions and Clinical Relevance—Zoledronate
may reduce subchondral bone loss and effect markers
of bone metabolism in dogs with experimentally
induced instability of the stifle joint and subsequent
development of osteoarthritis. (Am J Vet Res